Toll-like receptors in the pathogenesis of alcoholic liver disease

Jan Petrasek
University of Massachusetts Medical School

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation
Petrasek J, Mandrekar P, Szabo G. (2010). Toll-like receptors in the pathogenesis of alcoholic liver disease. Open Access Publications by UMass Chan Authors. https://doi.org/10.1155/2010/710381. Retrieved from https://escholarship.umassmed.edu/oapubs/2305

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Review Article
Toll-Like Receptors in the Pathogenesis of Alcoholic Liver Disease

Jan Petrasek, Pranoti Mandrekar, and Gyongyi Szabo
Department of Medicine, University of Massachusetts Medical School, LRB215, 364 Plantation Street, Worcester, MA 01605, USA

Correspondence should be addressed to Gyongyi Szabo, gyongyi.szabo@umassmed.edu

Received 20 May 2010; Accepted 20 July 2010

Academic Editor: Keigo Machida

Copyright © 2010 Jan Petrasek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the multifactorial pathophysiology of alcoholic liver disease (ALD), inflammatory cascade activation plays a central role. Recent studies demonstrated that Toll-like Receptors, the sensors of microbial and endogenous danger signals, are expressed and activated in innate immune cells as well as in parenchymal cells in the liver and thereby contribute to ALD. In this paper, we discuss the importance of gut-derived endotoxin and its recognition by TLR4. The significance of TLR-induced intracellular signaling pathways and cytokine production as well as the contribution of reactive oxygen radicals is evaluated. The contribution of TLR signaling to induction of liver fibrosis and hepatocellular cancer is reviewed in the context of alcohol-induced liver disease.

1. Introduction
Alcohol abuse is a leading cause of morbidity and mortality worldwide [1] and alcoholic liver disease (ALD), ranging from steatosis, steatohepatitis to fibrosis and cirrhosis, affects over 10 million Americans [2]. Liver injury mediated by alcohol involves both liver parenchymal and nonparenchymal cells, including resident and recruited immune cells that contribute to liver damage and inflammation [3]. The concept of dysregulated innate immunity as an indispensable component of alcohol-induced liver disease dates back to the observations that patients with ALD have increased antibodies against Escherichia coli in plasma [4] and that chronic alcohol administration increases gut-derived endotoxin in the portal circulation, activating resident liver macrophages to produce several proinflammatory cytokines [5, 6]. Recognition of Toll-like receptors (TLR) as the key components involved in activation of the innate immune system enabled a substantial progress in understanding of the mechanisms mediating alcohol-induced liver injury.

2. Gut-Derived Bacterial Components Are Critical in the Pathogenesis of ALD
Due to its unique anatomy and blood supply the liver receives blood from the intestine, exposing hepatocytes and cells in the liver sinusoids not only to nutrients but also to gut-derived microbial products. The gut mucosal epithelium serves as an interface between the vast microbiota and internal host tissues [7]. Under normal circumstances, a normal balance of gut barrier function, gut permeability, and equilibrium of commensal and pathogenic microorganisms in the gut lumen is maintained and mostly prevents microbial translocation from the gut [8]. Lipopolysaccharide (LPS, endotoxin), a component of Gram-negative bacterial wall, and other components derived from bacteria in the intestinal microflora normally penetrate the mucosa only in trace amounts, enter the portal circulation, and are cleared by 80%–90% in the liver through uptake by Kupffer cells (resident liver macrophages) and hepatocytes in a manner that prevents cell damage or inflammation [9, 10]. These physiological uptake and detoxification are important for preventing systemic reactions to gut-derived bacterial components.

Multiple lines of evidence support the hypothesis that gut-derived endotoxin is involved in alcoholic liver injury Figure 1(a). First, it has been shown that excessive intake of alcohol increases gut permeability of normally nonabsorbable substances [11]. Second, intestinal Gram-negative bacteria, as well as blood endotoxin, are increased in acute [12, 13] and chronic [12, 14, 15] alcohol feeding models. Patients with alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis have 5- to 20-fold increased plasma
endotoxin compared to normal subjects [8, 16] although it is unclear whether endotoxemia correlates with the extent of liver dysfunction [17, 18]. Third, intestinal sterilization with antibiotics [19] and displacement of Gram-negative bacteria with Lactobacillus treatment [20] prevented alcohol-induced liver injury. The mechanism underlying the disruption of the intestinal barrier appears to be multifactorial [21]. Disruption of tight junctions has been attributed to acetaldehyde [8] and liver-derived inflammatory cytokines, particularly TNF-α, that enter the systemic circulation and further disrupt tight junctions, thus perpetuating intestinal barrier dysfunction [22]. Gut permeability may be also increased by ethanol-induction of miR212, a microRNA that downregulates proteins of the zona occludens in intestinal cell culture and that was increased in colonic biopsy samples in patients with ALD [23].

Activation of Kupffer cells has been identified as one of the key elements in the pathogenesis of alcohol-induced liver damage. Kupffer cells are the largest population of tissue macrophages, predominantly distributed in the lumen of hepatic sinusoids, and exhibit endocytic activity against bloodborne materials entering the liver [10, 24]. Triggering of Toll-like receptor signaling drives Kupffer cells to produce inflammatory cytokines and chemokines and to initiate the inflammatory cascade [25]. Indeed, the essential role of Kupffer cells as a central component of the pathomechanism of ALD has been demonstrated in studies in mice and rats that show that inactivation of Kupffer cells with gadolinium chloride or liposomal clodronate can almost fully ameliorate alcohol-induced liver disease [26, 27].

3. Toll-Like Receptors Involved in ALD

The innate immune system recognizes conserved pathogen-associated molecular patterns, which are released during bacterial multiplication or when bacteria die or lyse [28], through pattern recognition receptors, including Toll-like receptors (TLRs) [29]. TLR4 recognizes endotoxin from Gram-negative bacteria, and TLR2 is essential for recognition of microbial lipopeptides, while TLR1 and 6 combined with TLR2 distinguish between triacyl- and diacyl-lipopeptides [30]. TLR3 recognizes viral double-stranded RNA, and TLR5 recognizes bacterial flagellin [31, 32]. TLR7 and TLR8 bind viral single-stranded RNA [33], and TLR9 recognizes prokaryotic CpG-rich DNA [34]. Kupffer cells express TLR4, TLR2, TLR3, and TLR9 [35–37], and hepatic stellate cells express TLR2, TLR4, and TLR9 [38, 39]. Liver sinusoidal endothelial cells express TLR4 [40, 41], and primary cultured hepatocytes express mRNA for all Toll-like receptors although they express very low levels of TLR2, TLR3, TLR4, and TLR5 and show weak responses in vivo [42, 43].

3.1. Role of TLRs in the Pathogenesis of Alcohol-Induced Liver Injury. Activation of Kupffer cells via TLR4-dependent mechanism plays a crucial role in the pathogenesis of alcohol-induced liver injury [6, 19, 44, 45]. LPS, a component of Gram-negative bacteria, is a potent activator of innate immune responses through its binding to the TLR4 complex and comprises three distinct parts: a carbohydrate (O-antigen), the oligosaccharide core region, and a lipid portion (Lipid A). Only the lipid A portion is immunogenic [46]. While TLR4 cannot directly bind LPS, the coreceptors CD14 and MD-2 bind LPS and upon LPS binding activate TLR4. CD14 is a GPI-anchored protein, which also exists in soluble form, and facilitates the transfer of LPS to the TLR4/MD-2 receptor complex that modulates LPS recognition [47]. MD-2 is a soluble protein that noncovalently associates with TLR4 and binds LPS directly to form a complex with LPS in the absence of TLRs [48]. The association between LPS and CD14 is facilitated by LPS-binding protein (LBP), which is a soluble protein that plays a critical role in alcohol-induced liver injury. Alcohol-induced liver injury was prevented in C3H/HeJ mice [50], which have a functional mutation in the TLR4 gene and have defective response to bacterial endotoxin [51]. Prevention of alcohol-induced liver inflammation and injury in C3H/HeJ mice was associated with decreased TNF-α expression, compared to wild-type mice. Similar protection from alcohol-induced liver injury was observed in mice deficient for LBP [52] and CD14 [53] whereas mice transgenic for human CD14 were hypersensitive to LPS [54].

Since disruption of intestinal barrier by ethanol increases permeability for macromolecular substances in general [8], it is likely that other bacterial components, in addition to LPS, are translocated to the portal blood in alcoholics. In particular, bacterial DNA was found in serum and ascites of patients with advanced liver cirrhosis leading to increased cytokine production in peritoneal macrophages [55–57]. Bacterial DNA, which is detected by TLR9, sensitizes the liver to injury induced by LPS via upregulation of TLR4, MD-2 and induction Th1-type immune response in the liver [58, 59]. Hepatic expression of TLR9 was increased in wild-type animals using the Lieber-DeCarli chronic alcohol feeding model, and alcohol feeding sensitized to LPS ligand CpG to enhance TNF-α production [60]. In patients with alcoholic cirrhosis, purified B cells stimulated with TLR9 ligand CpG ex vivo showed significant upregulation of immunoglobulin A, compared to B cells from control individuals [61], suggesting involvement of TLR pathways in alcohol-induced hyperimmunoglobulinemia [61–63]. Also, overexpression of TLR9, TLR4, and TLR2 was associated with impaired neutrophil function in alcoholic liver cirrhosis [64].

In addition to TLR4 and TLR9, increased expression of TLR1, 2, 6, 7, and 8 was observed in wild-type mice using the Lieber-DeCarli chronic alcohol feeding model, and feeding with alcohol resulted in sensitization to liver inflammation and damage because administration of TLR1, 2, 4, 6, 7, 8, and 9 ligands increased expression of TNF-α [60]. Interestingly, expression of these TLRs in mice on ethanol diet remained significantly increased in spite of concurrent administration of antibiotics that ameliorated liver injury [60]. Other investigations found that deficiency in TLR2 had no protective effect on alcohol-induced liver injury in a mouse model of chronic ethanol feeding [65] and that hepatic expression of TLR2 or TLR4 mRNA was
not changed by chronic alcohol feeding or by acute ethanol administration [66], implying that the increased sensitivity of alcoholic fatty livers to LPS occurs without upregulation of TLR2 or TLR4 genes and may be related to an imbalance of proinflammatory/oxidative and cytoprotective mechanisms.

Taken together, it seems likely that sensitization to TLR ligands in alcohol-induced liver damage is regulated by multiple mechanisms, including those that are directly dependent on gut-derived bacterial components and TLR signaling, but also other mechanisms, such as lipid accumulation in hepatocytes [66, 67], histone acetylation in ethanol-exposed macrophages [68], or activation of Kupffer cells by C3 and C5 components of the complement pathway [69].

3.1.1. MyD88-Independent and Dependent TLR Pathways in ALD. TLR4 is unique among TLRs in its ability to activate two distinct signaling pathways Figure 1(b). One pathway is activated by the adaptors TIRAP (Toll/interleukin-1-receptor- (TIR-) domain-containing adaptor protein) and MyD88, which leads to activation of NF-κB and to the induction of proinflammatory cytokines. The second pathway (MyD88-independent) is activated by the adaptors TRIF and TRAM (TRIF-related adaptor molecule), which activates the TBK/IKKε kinase and interferon regulatory factor 3 (IRF3) to induce Type I IFNs as well as NF-κB activation [70, 71]. The two TLR4-dependent signaling pathways are induced sequentially, and the TRAM-TRIF pathway is only operational from early endosomes following endocytosis of TLR4 [72].

Recent evidence suggests that TLR4 downstream signaling in ALD is mediated predominantly through MyD88-independent pathway, rather than through the MyD88-dependent mechanism. Alcohol feeding with the Lieber-DeCarli diet [73, 74] resulted in significant steatosis and liver damage in MyD88-deficient mice compared to mice on pair-fed diet, and the extent of alcohol-induced changes was comparable in alcohol-fed MyD88-deficient wild-type mice [65]. The involvement of the MyD88-independent TLR4 signaling pathway was indicated by upregulation of IRF7, an IRF3-inducible gene, in Kupffer cells [75]. In a different study it was reported that mice deficient in TRIF, which is a key TLR4 downstream adaptor in the MyD88-independent pathway, were protected against alcohol-induced liver disease, and it is likely that IRF3, a transcription factor downstream to TLR4/TRIF, binds to the TNF-α promoter resulting in induction of TNF-α [76]. These findings, together with the observation that mice deficient in IRF3 show protection against alcohol-induced liver injury (Szabo, unpublished data), demonstrate that TLR4-mediated signaling via MyD88-independent pathways is critical in induction of alcoholic liver disease.

3.1.2. Endotoxin Sensing and Loss of TLR Tolerance in ALD. Lipopolysaccharide is the most potent inducer of inflammatory cytokines, particularly TNF-α, in monocytes and macrophages. However, when LPS challenge is provided following an initial insult with LPS, induction of TNF-α is severely attenuated, a phenomenon called “LPS tolerance.”
Recent studies demonstrated that upregulation of negative regulators of TLR signaling play a central role in TLR tolerance [77–79]. Experimental evidence suggests, however, that TLR tolerance can be broken by multiple sequential LPS administration in vivo and in vitro [80]. When mice were injected with a single dose of LPS, a second LPS challenge failed to induce significant TNF-α induction compared to the initial dose demonstrating TLR4 tolerance [81]. However, when LPS was given in 3-day intervals for 5 repeated times, the TLR tolerance was lost and serum TNF-α levels induced by the last dose of LPS were comparable to TNF-α induced by a single LPS administration [9]. The bimodal effects of LPS on TNFα production are reminiscent to the opposite modulation of inflammation by acute and prolonged alcohol use. At the cellular and molecular level, acute alcohol administration inhibited while chronic alcohol use increased production of proinflammatory mediators particularly when LPS was used as an inflammatory insult [82]. Increased TNF-α production and NF-kB activation were found in monocytes of patients with alcoholic steatohepatitis [83].

In vitro studies showed that prolonged alcohol exposure of monocytes for 4 days or longer in vitro augmented LPS-induced TNF-α production compared to alcohol-naïve cells [84]. The involvement of the TLR4 signaling pathway was suggested by increased IRAK-1 phosphorylation, increased IKK kinase activity, increased NF-kB nuclear translocation and DNA transactivation in human monocytes [84]. This upregulation of TLR4 signaling in the presence of diminished expression of IRAK-M in monocytes after prolonged alcohol treatment. Overexpression of IRAK-M prevented the increased LPS-induced TNF-α production in chronic alcohol-treated cells suggesting that loss of IRAK-M is likely to contribute to the loss of TLR tolerance in monocytes after prolonged alcohol exposure [84].

Previous studies have demonstrated that chronic alcohol use results in increased levels of LPS in the portal and systemic circulation that may mediate or amplify the loss of TLR tolerance in monocytes after prolonged alcohol exposure [84].

The importance of molecular mechanisms culminating in nuclear events leading to activation of a wide array of transcription factors in various liver cell types is widely studied in progression of alcoholic liver injury. These transcription factors bind to the promoter regions in target genes resulting in induction of cytokines, chemokines, and various other mediators including kinases, adaptor proteins, and receptors. Studies using rodent models of alcoholic liver injury show that exposure to chronic alcohol increases expression of genes related to fatty acid synthesis and decreases fatty acid oxidation-related gene expression. Transcription factors such as sterol regulatory binding protein (SREBP) and peroxisome proliferator factor α (PPARα) play a pivotal role in fatty acid metabolism and are altered during chronic alcohol consumption. Liver-specific overexpression of SREBP-1α and SREBP-1c is observed in alcoholic liver injury leading to increased hepatic triglyceride content [86]. On the other hand PPARα expression and DNA binding activity were decreased in alcoholic livers resulting in decreased fatty acid oxidation [87]. Similar to alterations in transcription factors related to fatty acid metabolism, chronic alcohol-induced inflammatory mediators are also modulated by key transcription factors. The most studied transcription factor is NFκB, and alteration in its DNA binding activity has been observed in livers following chronic alcohol consumption [58] as well as in isolated monocytes/macrophages [88]. Chronic alcohol increased NFκB activity in monocytes and macrophages leading to an upregulation in various inflammatory cytokine and chemokine genes [89, 90]. Another transcription factor modulated by chronic alcohol exposure is AP-1 wherein increased expression and activity were observed in livers of chronic alcohol-fed mice [91]. Activation of PPARγ, another transcription factor, was beneficial and prevented chronic alcohol-induced liver injury in mice [92]. While PPARγ is thought to be involved in anti-inflammatory cytokine production, its exact mechanism in alcoholic livers is not known. Furthermore Egr-1, another zinc finger transcription factor, is up-regulated in LPS-stimulated isolated Kupffer cells from chronic alcohol-fed mice and is dependent on ERK activation [93]. Egr-1 knockout mice were protective to alcoholic liver injury, indicating a role for the Egr-1-ERK pathway in the pathogenesis of alcoholic liver injury [94]. Thus, studies so far suggest that transcription factors play an important role in alcoholic liver injury, and future investigations are necessary to determine the complexity of regulation of the target genes in various liver types during alcoholic liver disease.

5. Proinflammatory Cytokine Induction in ALD

Alcoholic steatohepatitis is characterized by infiltration of various inflammatory cells in the liver, including monocytes, macrophages, neutrophils, and lymphocytes, which occurs as a consequence of activation of inflammatory mediators induced by TLR signaling [95, 96]. In humans with alcoholic steatohepatitis, serum TNF-α, IL-6, and IL-8 levels are increased, and their levels correlate with markers of the acute-phase response, liver function, and clinical outcome [97]. There is also evidence for activation of circulating monocytes in individuals with ALD, based on increased TNF-α production and increased NFκB activation [98–100].

Induction of TNF-α by TLR4 signaling and by reactive oxygen species in Kupffer cells has been identified as a major component in ALD [85, 101, 102]. The effect of TNF-α in hepatic inflammation and hepatocyte apoptosis is mediated through TNF receptor TNF-R1 [101]. Binding of TNF-α to TNF-R1 activates several signal transduction pathways [103], resulting in the activation transcription factors including NFκB and c-Jun-N-terminal kinase [104] and in activation of proapoptotic Fas-associated death domain [105].

Circulating levels of TNF-α and TNF-R1 are higher in patients with alcoholic steatohepatitis than in heavy drinkers with inactive cirrhosis, heavy drinkers who do not have...
liver disease, and individuals with neither alcoholism nor liver disease [45, 83, 106]. High serum levels of TNF-α and TNF-R1 correlated with mortality in patients with acute alcoholic hepatitis [106–108]. Hepatic expression of TNF-R1 is enhanced in chronic ethanol consumption [109], and liver injury is substantially reduced when alcohol diet is administered in TNF receptor 1 (TNF-R1)—knockout mice or in rats that have been pretreated with anti-TNF-α antibodies or thalidomide, which reduces production of TNF-α [110, 111].

Under normal circumstances, hepatocytes are resistant to the proapoptotic effect of TNF-α; however, several conditions prime hepatocytes to TNF-α-mediated cell death in the setting of chronic alcohol consumption [112–115]. Hepatocytes from rats chronically fed alcohol have increased TNF-α induced cytotoxicity associated with mitochondrial permeability transition pore opening [114] and with a profound effect of alcohol on mitochondrial functional integrity [115, 116]. Also, decreased mitochondrial glutathione in alcohol-fed rats [117] or inhibition of hepatic transmethylation reactions by S-adenosylhomocysteine [113] has been shown to sensitize hepatocytes to TNF-α mediated cytotoxicity. Moreover, animal models of alcohol-induced liver injury show impaired function of proteasomes that increases hepatocyte sensitivity to TNF-α-mediated apoptosis [118]. Interestingly, although upregulation of TNF-R1 is observed in the livers of patients with alcoholic steatohepatitis [109], a recent in vitro study showed that free fatty acids sensitized HepG2 cells to TRAIL-mediated apoptosis, but not to cytotoxicity mediated by TNF-α [67].

In addition to the metabolic changes involved in sensitization to TNF-α cytotoxicity, the net effect of TNF-α on hepatocytes is influenced by other cytokines. For example, in mice that are deficient in IL-6, increased production of TNF-α induced by partial hepatectomy promotes death of hepatocytes instead of stimulating their proliferation [119]. Similarly, deficiency of IL-10, an anti-inflammatory cytokine inducible by adiponectin [120], exacerbates TNF-α-mediated liver injury in mice by alcohol [121]. Conversely, mice that are deficient in interleukin-12 [122], interferon-γ [123], or interleukin-18 [124] are protected against TNF-α-induced liver damage. The subtle balance between hepatocyte proliferation and apoptosis is also regulated by an autocrine cascade involving the pro-proliferative TGF-α and IL-1 receptor antagonist, and the antiproliferative IL-1β [125].

6. Toll-Like Receptors and Oxidative Stress in ALD

Cellular responses induced by oxidative stress play an important role in innate immune cell activation. Kupffer cells produce reactive oxygen species (ROS) in response to chronic alcohol exposure as well as endotoxin [126]. Interaction of NADPH with TLR4 is involved in LPS-mediated ROS generation and NFκB activation and production of inflammatory cytokines in neutrophils [127] and in human monocytes [128]. Pretreatment of chronic alcohol fed rats with inhibitor of NADPH oxidase diphenyleneiodonium (DPI) normalized ROS production, decreased LPS-induced ERK1/2 phosphorylation, and inhibited increased TNF-α production in Kupffer cells [126]. Inhibition of NADPH oxidase prevented steatosis, upregulation of TLR2, 4, 6, and 9 mRNA, and sensitization to respective ligand-induced liver injury [60], indicating a crosstalk between oxidative stress and TLR pathways in ALD. Protection from alcohol-induced liver injury was observed in p47 phox−/− mice, deficient in the main cytosolic component of NADPH oxidase, further supporting the important role of NADPH oxidase in alcohol-induced inflammatory response and liver injury [126].

7. TLR Signaling as Target for Therapy of ALD

Recently, a number of different approaches that modulate TLR signaling have been developed. These approaches include modulation of TLR ligand release from the intestine by probiotics [129, 130], activation of TLR signaling by synthetic TLR ligands [131–133], inhibition of TLR activation by small molecule inhibitors [134–136], and interference with cytokines induced by TLR signaling [137–139]. So far, probiotics and anticytokine therapeutic approaches have progressed into clinical trials in patients with ALD [129, 139, 140].

Modulation of intestinal microbiota using probiotics has been shown to reduce bacterial translocation [141, 142], circulating endotoxin levels in animal models [143], and bacterial infection, a marker for bacterial translocation, in patients with liver cirrhosis [144, 145]. Beneficial effects of probiotics have been reported in an animal model of alcohol-induced liver injury [20] and of LPS-induced liver injury [142, 146]. Patients with alcoholic liver cirrhosis treated with Lactobacillus casei Shirotta three times daily for 4 weeks showed restoration of deranged neutrophil phagocytic capacity, compared to controls [130]. A recent open-label pilot trial showed that a 5-day administration of Bifidobacterium bifidum and Lactobacillus plantarum in alcohol-addicted psychiatric patients with mild alcoholic hepatitis ameliorated serum markers of liver injury to a significantly higher extent compared to control group treated with abstinence only [129]. These data suggest that modulation of the bowel flora may play a role in the pathogenesis and treatment of ALD and indicate a need for larger and rigorously designed clinical trials to support the use of probiotics in ALD.

While the role of TNF-α in the development of ALD has been well characterized [147], clinical investigations of the therapeutic efficacy of antibodies to TNF-α (e.g., infliximab) to treat patients with acute alcoholic hepatitis have generated variable results [139, 148]. There is particular concern about off-target effects of completely inhibiting TNF-α function. For example, since TNF-α is a critical component of immunity, infectious disease is a primary concern during TNF-α therapy [139, 149]. Moreover, TNF-α is required for normal liver regeneration as hepatocyte proliferation in response to injury is impaired in mice lacking TNF-α receptors [150]. Etanercept, a TNF-α neutralizing antibody,
appeared to increase short-term survival of patients with alcoholic hepatitis in a small pilot study [151] although a subsequent randomized, placebo-controlled trial conducted by the same investigators showed a worse 6-month survival rate in the group treated with etanercept than in the placebo group [152].

8. Alcohol: TLR Signaling and Liver Fibrosis

Alcohol-induced liver fibrosis is characterized by excessive deposition of extracellular matrix components due to increased matrix production and decreased matrix degradation [153]. Ethanol contributes to liver fibrosis in several aspects, including the upregulation of collagen transcription in hepatic stellate cells by acetaldehyde or reactive oxygen species from ethanol-exposed hepatocytes [154–157]. Also, in hepatic stellate cells by acetaldehyde or reactive oxygen aspects, including the upregulation of collagen transcription approximately fourfold increase in the risk of hepatocellular carcinoma (HCC) [166]. The five-year cumulative incidence of HCC reaches 8% [167]. In addition, alcohol shows synergy with chronic hepatitis infection [168]. For example, the relative risk of developing HCC was 50-fold higher in heavy drinkers with chronic hepatitis C (HCV) whereas nondrinking HCV patients showed 15-fold increased risk, compared to abstaining controls without HCV [166].

Studies investigating the synergism between alcohol and HCV focused at the structural HCV core [169–171] and the nonstructural NS5A proteins [172, 173]. The HCV core protein causes overproduction of reactive oxygen species [169], induces insulin resistance [171], and inhibits very low density lipoprotein secretion from hepatocytes, contributing to steatosis [170]. However, although HCV core-transgenic mice fed with ethanol for 9 months have shown increased incidence of HCC, the mechanism of synergism between the HCV core protein and ethanol in hepatic carcinogenesis is not known [174].

Recently, the role of TLR4 in the synergism between alcohol and HCV nonstructural protein NS5A in hepatic oncogenesis has been proposed [175]. In a study with NS5A transgenic mice (NS5A Tg), it was reported that NS5A induces TLR4 expression in the liver. NS5A Tg mice developed fulminant hepatitis after administration of a single dose of LPS and showed aggravated alcoholic steatohepatitis after 4-week intragastric ethanol feeding [172]. Importantly, the adjuvant effect of NS5A was blunted in NS5A Tg mice who were deficient in TLR4 or who underwent gut sterilization with antibiotics, indicating the importance of endotoxin and TLR4 signaling in the synergism between alcohol/LPS and NS5A.

Furthermore, one-fourth of NS5A Tg mice fed Lieber-DeCarli ethanol diet for 12 months developed HCC, in contrast to no tumors found in WT or TLR4−/− NS5A mice, demonstrating that alcohol and NS5A synergistically induce liver tumors through TLR4 signaling [172]. Microarray analysis showed that NS5A Tg mice fed ethanol have increased liver expression of the stem/progenitor cell marker Nanog, which is involved in the genesis of CD133+ cancer stem cells. Nanog induction was dependent on NS5A and alcohol and was abrogated in TLR4−/− NS5A Tg mice fed alcohol. Further experiments demonstrated that Nanog is a novel downstream gene of TLR4 signaling. Transplantation of p53-deficient hepatic progenitor cells transduced with Nanog or TLR4 resulted in spontaneous tumor development after 80 days or after repetitive LPS injections for 25 weeks, respectively. The tumor incidence caused by TLR4 transduction and LPS injections was reduced by coexpression of short hairpin RNA against Nanog, indicating that Nanog expression is involved in tumor formation and growth in this model [172]. Further experiments showed that Nanog-positive cancer stem cells did not upregulate TGF-β signaling after TLR4 activation [173]. Defective TGF-β pathway leads to spontaneous development of HCC [176].

Taken together, the recent data [172, 173] suggest that alcohol and HCV NS5A induce synergistic tumor development via induction and activation of TLR4 in mice and that this synergism involves the stem cell marker Nanog, which is
a TLR4-downstream regulated gene. These findings indicate that inhibition of TLR4 signaling may provide a therapeutic option for HCV-associated liver tumors.

10. Conclusion

In conclusion, there is clear evidence that alcohol consumption leads to increased intestinal permeability and endotoxemia, which results in activation of innate immunity via TLR4 signaling. Recent studies have contributed to the dissection of molecular mechanisms of TLR4 signaling in ALD, indicating the indispensable role of MyD88-independent pathway in mediating the effects of gut-derived endotoxin in ALD and suggesting the role of other TLRs in modulation of alcohol-induced liver injury. Moreover, novel data provide insight into the mechanisms of prolonged alcohol exposure on TLR4-induced inflammation and loss of LPS tolerance and the interplay between proinflammatory and anti-inflammatory cytokines mediating TLR-induced cytotoxicity. Further studies are needed to evaluate crosstalk between liver parenchymal and nonparenchymal cells. Understanding the cell-specific role of TLR signaling in ALD will further provide new insights into the pathogenesis of ALD and will reveal new targets for therapeutic intervention.

References

[1] J. Rehm, R. Room, M. Monteiro et al., “Alcohol as a risk factor for global burden of disease,” European Addiction Research, vol. 9, no. 4, pp. 157–164, 2003.
[2] S. J. Mills and S. A. Harrison, “Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease,” Current Gastroenterology Reports, vol. 7, no. 1, pp. 32–36, 2005.
[3] S. L. Friedman, “Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury,” Journal of Biological Chemistry, vol. 275, no. 4, pp. 2247–2250, 2000.
[4] P. Staun Olsen, M. Bjorneboe, and H. Prytz, “Escherichia coli antibodies in alcoholic liver disease. Correlation to alcohol consumption, alcoholic hepatitis, and serum IgA,” Scandinavian Journal of Gastroenterology, vol. 18, no. 7, pp. 889–896, 1983.
[5] A. A. Nanji, U. Khettry, S. M. H. Sadrazadeh, and T. Yamanaka, “Severity of liver injury in experimental alcoholic liver disease: correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2,” American Journal of Physiology, vol. 142, no. 2, pp. 367–373, 1993.
[6] N. Enomoto, K. Ikekima, B. Bradford et al., “Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin,” Gastroenterology, vol. 115, no. 2, pp. 443–451, 1998.
[7] B. A. Duerkop, S. Vaishnava, and L. V. Hooper, “Immune responses to the microbiota at the intestinal mucosal surface,” Immunity, vol. 31, no. 3, pp. 368–376, 2009.
[8] R. Rao, “Endotoxemia and gut barrier dysfunction in alcoholic liver disease,” Hepatology, vol. 50, no. 2, pp. 638–644, 2009.
[9] J. Roth, J. L. McClellan, M. J. Kluger, and E. Zeisberger, “Attenuation of fever and release of cytokines after repeated injections of lipopolysaccharide in guinea-pigs,” Journal of Physiology, vol. 477, part 1, pp. 177–185, 1994.
[10] B. Benacerraf, M. M. Sebestyen, and S. Schlossman, “A quantitative study of the kinetics of blood clearance of P32-labelled Escherichia coli and Staphylococci by the reticuloendothelial system,” The Journal of Experimental Medicine, vol. 110, no. 1, pp. 27–48, 1959.
[11] I. Bjarnason, K. Ward, and T. J. Peters, “The leaky gut of Alcoholism: Clinical and Experimental Research: possible route of entry for toxic compounds,” The Lancet, vol. 1, no. 8570, pp. 179–182, 1984.
[12] P. Mathurin, Q.-G. Deng, A. Keshavarzian, S. Choudhary, E. W. Holmes, and H. Tsukamoto, “Exacerbation of alcoholic liver injury by enteral endotoxin in rats,” Hepatology, vol. 32, no. 5, pp. 1008–1017, 2000.
[13] A. A. Nanji, K. Jokelainen, M. Fotouhinia et al., “Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines,” American Journal of Physiology, vol. 281, no. 6, pp. G1348–G1356, 2001.
[14] K. Jokelainen, L. A. Reinke, and A. A. Nanji, “NF-kB activation is associated with free radical generation and endotoxemia and precedes pathological liver injury in experimental alcoholic liver disease,” Cytokine, vol. 16, no. 1, pp. 36–39, 2001.
[15] R. K. Rao, A. Seth, and P. Sheth, “Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease,” American Journal of Physiology, vol. 286, no. 6, pp. G881–G884, 2004.
[16] H. Fukui, B. Brauner, J. C. Bode, and C. Bode, “Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay,” Journal of Hepatology, vol. 12, no. 2, pp. 162–169, 1991.
[17] M. Fujimoto, M. Uemura, Y. Nakatani et al., “Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance,” Alcoholism: Clinical and Experimental Research, vol. 24, no. 4, pp. 485–545, 2000.
[18] S. L. Schafer, R. Lin, P. A. Moore, J. Hiscott, and P. M. Pitha, “Regulation of type I interferon gene expression by interferon regulatory factor-3,” Journal of Biological Chemistry, vol. 273, no. 5, pp. 2714–2720, 1998.
[19] Y. Adachi, L. E. Moore, B. U. Bradford, W. Gao, and R. G. Thurman, “Antibiotics prevent liver injury in rats following long-term exposure to ethanol,” Gastroenterology, vol. 108, no. 1, pp. 218–224, 1995.
[20] A. A. Nanji, U. Khettry, and S. M. H. Sadrazadeh, “Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease,” Proceedings of the Society for Experimental Biology and Medicine, vol. 205, no. 3, pp. 243–247, 1994.
[21] C. Bode and J. C. Bode, “Effect of alcohol consumption on the gut,” Bailliere’s Best Practice and Research in Clinical Gastroenterology, vol. 17, no. 4, pp. 575–592, 2003.
[22] S. Yajima, H. Morisaki, R. Serita et al., “Tumor necrosis factor-α mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia,” Critical Care Medicine, vol. 37, no. 3, pp. 1024–1030, 2009.
[23] Y. Tang, A. Banan, C. B. Forsyth et al., “Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease,” Alcoholism: Clinical and Experimental Research, vol. 32, no. 2, pp. 355–364, 2008.
[25] E. Seki and D. A. Brenner, “Toll-like receptors and adaptor molecules in liver disease: update,” Hepatology, vol. 48, no. 1, pp. 322–335, 2008.
[26] Y. Adachi, B. U. Bradford, W. Gao, H. K. Bojes, and R. G. Thurman, “Inactivation of Kupffer cells prevents early alcohol-induced liver injury,” Hepatology, vol. 20, no. 2, pp. 453–460, 1994.
[27] D. R. Koop, B. Klopfenstein, Y. Iimuro, and R. G. Thurman, “Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1,” Molecular Pharmacology, vol. 51, no. 6, pp. 944–950, 1997.
[28] J. Hellman, P. M. Loiselle, M. M. Tehan et al., “Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum,” Infection and Immunity, vol. 68, no. 5, pp. 2566–2572, 2000.
[29] S. Akira, K. Takeda, and T. Kaisho, “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunology, vol. 2, no. 8, pp. 675–680, 2001.
[30] K. Takeda, O. Takeuchi, and S. Akira, “Recognition of lipopolysaccharides by Toll-like receptors,” Journal of Endotoxin Research, vol. 8, no. 6, pp. 459–463, 2002.
[31] L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001.
[32] F. Hayashi, K. D. Smith, A. Ozinsky et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5,” Nature, vol. 410, no. 6832, pp. 1099–1103, 2001.
[33] F. Heil, H. Hemmi, H. Hochrein et al., “Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8,” Science, vol. 303, no. 5663, pp. 1526–1529, 2004.
[34] H. Hemmi, O. Takeuchi, T. Kawai et al., “A Toll-like receptor recognizes bacterial DNA,” Nature, vol. 408, no. 6813, pp. 740–745, 2000.
[35] B. M. Thobe, M. Frink, E. Hildebrand et al., “The role of MAPK in Kupffer cell Toll-like receptor (TLR) 2, TLR4, and TLR9-mediated signaling following trauma-hemorrhage,” Journal of Cellular Physiology, vol. 210, no. 3, pp. 667–675, 2007.
[36] J. Wu, M. Lu, Z. Meng et al., “Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice,” Hepatology, vol. 46, no. 6, pp. 1769–1778, 2007.
[37] M. Schuchmann, F. Hermann, J. Herkel, R. Van Der Zee, P. R. Galle, and A. W. Lohse, “HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells,” Immunology Letters, vol. 93, no. 2–3, pp. 199–204, 2004.
[38] A. Watanabe, A. Hashmi, D. A. Gomes et al., “Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9,” Hepatology, vol. 46, no. 5, pp. 1509–1518, 2007.
[39] Y.-H. Paik, K. S. Lee, H. J. Lee et al., “Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid,” Laboratory Investigation, vol. 86, no. 7, pp. 676–686, 2006.
[40] A. Uhrig, R. Banafsche, M. Kremer et al., “Development and functional consequences of LPS tolerance in sinusoidal endothelial cells of the liver,” Journal of Leukocyte Biology, vol. 77, no. 5, pp. 626–633, 2005.
[41] T. G. Sarphie, N. B. D’Souza, and I. V. Deaciu, “Kupffer cell inactivation prevents lipopolysaccharide-induced structural changes in the rat liver sinusoid: an electron-microscopic study,” Hepatology, vol. 23, no. 4, pp. 788–796, 1996.
[42] S. Liu, D. J. Gallo, A. M. Green et al., “Role of toll-like receptors in changes in gene expression and NF-kB activation in mouse hepatocytes stimulated with lipopolysaccharide,” Infection and Immunity, vol. 70, no. 7, pp. 3433–3442, 2002.
[43] M. Isogawa, M. D. Robek, Y. Furuichi, and E. V. Chisari, “Toll-like receptor signaling inhibits hepatitis B virus replication in vivo,” Journal of Virology, vol. 79, no. 11, pp. 7269–7272, 2005.
[44] L. E. Nagy, “Recent insights into the role of the innate immune system in the development of alcoholic liver disease,” Experimental Biology and Medicine, vol. 228, no. 8, pp. 882–890, 2003.
[45] R. G. Thurman, “II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin,” American Journal of Physiology, vol. 275, no. 4, pp. G605–G611, 1998.
[46] C. R. H. Raetz, C. M. Reynolds, M. S. Trent, and R. E. Bishop, “Lipid a modification systems in gram-negative bacteria,” Annual Review of Biochemistry, vol. 76, pp. 295–329, 2007.
[47] S. D. Wright, R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison, “CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein,” Science, vol. 249, no. 4975, pp. 1431–1433, 1990.
[48] R. Shimazu, S. Akashi, H. Ogata et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1777–1782, 1999.
[49] S. D. Wright, P. S. Tobias, R. J. Ulevitch, and R. A. Ramos, “Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages,” Journal of Experimental Medicine, vol. 170, no. 4, pp. 1231–1241, 1989.
[50] T. Uesugi, M. Froh, G. E. Arteel, B. U. Bradford, and R. G. Thurman, “Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice,” Hepatology, vol. 34, no. 1, pp. 101–108, 2001.
[51] B. M. Sulzter, “Genetic control of leucocyte responses to endotoxin,” Nature, vol. 219, no. 5160, pp. 1253–1254, 1968.
[52] T. Uesugi, M. Froh, G. E. Arteel et al., “Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice,” Journal of Immunology, vol. 168, no. 6, pp. 2963–2969, 2002.
[53] M. Yin, B. U. Bradford, M. D. Wheeler et al., “Reduced early alcohol-induced liver injury in CD14-deficient mice,” Journal of Immunology, vol. 166, no. 7, pp. 4737–4742, 2001.
[54] E. Ferrero, D. Jiao, B. Z. Tsuberi et al., “Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2380–2384, 1993.
[55] R. Francés, S. Benlloch, P. Zapater et al., “A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites,” Hepatology, vol. 39, no. 2, pp. 484–491, 2004.
[56] J. Such, R. Francés, C. Muoz et al., “Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites,” Hepatology, vol. 36, no. 1, pp. 135–141, 2002.
[57] R. Francés, C. Muñoz, P. Zapater et al., “Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients
with cirrhosis and ascites,” Gut, vol. 53, no. 6, pp. 860–864, 2004.

[58] L. Romics Jr., A. Dolganiiuc, A. Velayudham et al., “Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propionibacterium acnes,” Journal of Leukocyte Biology, vol. 78, no. 6, pp. 1255–1264, 2005.

[59] L. Romics Jr., A. Dolganiiuc, K. Kodysy et al., “Selective priming to toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in mice,” Hepatology, vol. 40, no. 3, pp. 553–564, 2004.

[60] T. Gustot, A. Lemmers, C. Moreno et al., “Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver,” Hepatology, vol. 43, no. 5, pp. 989–1000, 2006.

[61] B. Massonnet, A. Delwail, J.-M. Ayrault, C. Chagnue-Derode, J.-C. Lecron, and C. Silvain, “Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation,” Clinical and Experimental Immunology, vol. 158, no. 1, pp. 115–124, 2009.

[62] A. Van de Wiel, H. J. Schuurman, and L. Kater, “Alcoholic liver disease: an IgA-associated disorder,” Scandinavian Journal of Gastroenterology, vol. 22, no. 9, pp. 1025–1030, 1987.

[63] F. Gomez, P. Ruiz, and A. D. Schreiber, “Impaired function of macrophage Fcγ receptors and bacterial infection in alcoholic cirrhosis,” The New England Journal of Medicine, vol. 331, no. 17, pp. 1122–1128, 1994.

[64] V. Stadlbauer, R. P. Mookerjee, G. A. K. Wright et al., “Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis,” American Journal of Physiology, vol. 296, no. 1, pp. G15–G22, 2009.

[65] I. Hritz, P. Mandrekar, A. Velayudham et al., “The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88,” Hepatology, vol. 48, no. 4, pp. 1224–1231, 2008.

[66] L. Romics Jr., P. Mandrekar, K. Kodysy et al., “Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression,” Alchoholism: Clinical and Experimental Research, vol. 29, no. 6, pp. 1018–1026, 2005.

[67] H. Malhi, F. J. Barreyro, H. Isomoto, S. F. Bronk, and G. J. Gores, “Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity,” Gut, vol. 56, no. 8, pp. 1124–1131, 2007.

[68] S. E. W. Kendrick, G. O’Boyle, J. Mann et al., “Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis,” Hepatology, vol. 51, no. 6, pp. 1988–1997, 2010.

[69] S. Roychowdhury, M. R. McMullen, M. T. Pritchard et al., “An early complement-dependent and TLR4-independent phase in the pathogenesis of ethanol-induced liver injury in mice,” Hepatology, vol. 49, no. 4, pp. 1326–1334, 2009.

[70] M. W. Covert, T. H. Leung, J. E. Gaston, and D. Baltimore, “Achieving stability of lipopolysaccharide-induced NF-kB activation,” Science, vol. 309, no. 5742, pp. 1854–1857, 2005.

[71] G. M. Barton and R. Medzhitow, “Toll-like receptor signaling pathways,” Science, vol. 300, no. 5625, pp. 1524–1525, 2003.

[72] J. C. Kagan, T. Su, T. Horng, A. Chow, S. Akira, and R. Medzhitow, “TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β,” Nature Immunology, vol. 9, no. 4, pp. 361–368, 2008.

[73] C. S. Lieber and L. M. DeCarli, “The feeding of alcohol in liquid diets: two decades of applications and 1982 update,” Alcoholism: Clinical and Experimental Research, vol. 6, no. 4, pp. 523–531, 1982.

[74] C. S. Lieber and L. M. DeCarli, “Alcoholic liver injury: experimental models in rats and baboons,” Advances in Experimental Medicine and Biology, vol. 59, pp. 379–393, 1975.

[75] P. Morin, J. Bragança, M.-T. Bandu et al., “Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription,” Journal of Molecular Biology, vol. 316, no. 5, pp. 1009–1022, 2002.

[76] X.-J. Zhao, Q. Dong, J. Bindas et al., “TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol,” Journal of Immunology, vol. 181, no. 5, pp. 3049–3056, 2008.

[77] W. Piao, C. Song, H. Chen et al., “Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-β-dependent pathways and increases expression of negative regulators of TLR signaling,” Journal of Leukocyte Biology, vol. 86, no. 4, pp. 863–875, 2009.

[78] D. De Nardo, T. Nguyen, J. A. Hamilton, and G. M. Schola, “Down-regulation of IRAK-4 is a component of LPS- and CpG DNA-induced tolerance in macrophages,” Cellulair Signalling, vol. 21, no. 2, pp. 246–252, 2009.

[79] Y. Huang, L. M. Blatt, and M. W. Taylor, “Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1β and induction of interleukin-1 receptor antagonist,” Journal of Interferon and Cytokine Research, vol. 15, no. 4, pp. 317–321, 1995.

[80] A. E. Medvedev, I. Sabroe, J. D. Hasday, and S. N. Vogel, “Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease,” Journal of Endotoxin Research, vol. 12, no. 3, pp. 133–150, 2006.

[81] A. Dolganiiuc, O. Norkina, K. Kodysy et al., “Viral and Host Factors Induce Macrophage Activation and Loss of Toll-Like Receptor Tolerance in Chronic HCV Infection,” Gastroenterology, vol. 133, no. 5, pp. 1627–1636, 2007.

[82] K. A. Messingham, D. E. Faunce, and E. J. Kovacs, “Alcohol, injury, and cellular immunity,” Alcohol, vol. 28, no. 3, pp. 137–149, 2002.

[83] C. J. McClain and D. A. Cohen, “Increased tumor necrosis factor production by monocytes in alcoholic hepatitis,” Hepatology, vol. 9, no. 3, pp. 349–351, 1989.

[84] P. Mandrekar, S. Bala, D. Catalano, K. Kodysy, and G. Szabo, “The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes,” Journal of Immunology, vol. 183, no. 2, pp. 1320–1327, 2009.

[85] G. Szabo and P. Mandrekar, “A recent perspective on alcohol, immunity, and host defense,” Alcoholism: Clinical and Experimental Research, vol. 33, no. 2, pp. 220–232, 2009.

[86] M. You and D. W. Crabb, “Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins,” Alcohol, vol. 34, no. 1, pp. 39–43, 2004.

[87] A. A. Nanji, A. J. Dannenberg, K. Jokelainen, and N. M. Bass, “Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-α (PPARα)-regulated genes and is ameliorated by PPARα activation,” Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 1, pp. 417–424, 2004.
[88] P. Mandrekar and G. Szabo, “Signalling pathways in alcohol-induced liver inflammation,” Journal of Hepatology, vol. 50, no. 6, pp. 1258–1266, 2009.

[89] A. S. Baldwin Jr., “The NF-κB and IκB proteins: new discoveries and insights,” Annual Review of Immunology, vol. 14, pp. 649–681, 1996.

[90] S. Ghosh, M. J. May, and E. B. Kopp, “NF-κB and rel proteins: evolutionarily conserved mediators of immune responses,” Annual Review of Immunology, vol. 16, pp. 225–260, 1998.

[91] S. M. Yeligar, K. Machida, H. Tsukamoto, and V. K. Kalra, “Ethanol augments RANTES/CCL5 expression in rat liver sinusoidal endothelial cells and human endothelial cells via activation of NF-kappa B, HIF-1 alpha, and AP-1,” Journal of Immunology, vol. 183, no. 9, pp. 5964–5976, 2009.

[92] N. Enomoto, Y. Takei, M. Hirose et al., “Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 846–854, 2003.

[93] L. Shi, R. Kishore, M. R. McMullen, and L. E. Nagy, “Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages. Contribution to enhanced tumor necrosis factor a production,” Journal of Biological Chemistry, vol. 277, no. 17, pp. 14777–14785, 2002.

[94] M. R. McMullen, M. T. Pritchard, Q. Wang, C. A. Millward, C. M. Croniger, and L. E. Nagy, “Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice,” Gastroenterology, vol. 128, no. 7, pp. 2066–2076, 2005.

[95] U. M. Apte, A. Banerjee, R. McRee, E. Wellberg, and S. K. Ramaiah, “Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis,” Toxicology and Applied Pharmacology, vol. 207, no. 1, pp. 25–38, 2005.

[96] S. K. Ramaiah and H. Jaeschke, “Hepatic neutrophil infiltration during alcoholic steatohepatitis,” Toxicology and Applied Pharmacology, vol. 183, no. 9, pp. 5964–5976, 2009.

[97] C. J. McClain, S. Barve, I. Deaciuc, M. Kugelmas, and D. Hill, “Cytokines in alcoholic liver disease,” Seminars in Liver Disease, vol. 19, no. 2, pp. 205–220, 1999.

[98] L. Gobejishvili, S. Barve, S. Joshi-Barve, S. Uriarte, Z. Song, and C. McClain, “Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kB activity and TNF expression: relevance to alcoholic liver disease,” American Journal of Physiology, vol. 291, no. 7, pp. G681–G688, 2006.

[99] J. Latvala, J. Hietala, H. Koivisto, K. Järvi, P. Anttila, and O. Niemelä, “Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease,” American Journal of Gastroenterology, vol. 100, no. 6, pp. 1303–1310, 2005.

[100] C. J. McClain, D. B. Hill, Z. Song, I. Deaciuc, and S. Barve, “Monocyte activation in alcoholic liver disease,” Alcohol, vol. 27, no. 1, pp. 53–61, 2002.

[101] M. Yin, M. D. Wheeler, H. Kono et al., “Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice,” Gastroenterology, vol. 117, no. 4, pp. 942–952, 1999.

[102] H. Tsukamoto, Y. Takei, C. J. McClain et al., “How is the liver primed or sensitized for alcoholic liver disease?” Alcoholism: Clinical and Experimental Research, vol. 25, no. 5, pp. 1718–1815, 2001.

[103] G. Chen and D. V. Goeddel, “TNF-R1 signaling: a beautiful pathway,” Science, vol. 296, no. 5573, pp. 1634–1635, 2002.

[104] R. M. Locksley, N. Killeen, and M. J. Lenardo, “The TNF and TNF receptor superfamilies: integrating mammalian biology,” Cell, vol. 104, no. 4, pp. 487–501, 2001.

[105] N. S. Wilson, V. Dixo, and A. Ashkenazi, “Death receptor signal transducers: nodes of coordination in immune signaling networks,” Nature Immunology, vol. 10, no. 4, pp. 348–355, 2009.

[106] G. L. A. Bird, N. Sheron, A. K. J. Goka, G. J. Alexander, and R. S. Williams, “Increased plasma tumor necrosis factor in severe alcoholic hepatitis,” Annals of Internal Medicine, vol. 112, no. 12, pp. 917–920, 1990.

[107] S. Naveau, D. Emuile, A. Balian et al., “Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity,” Journal of Hepatology, vol. 28, no. 5, pp. 778–784, 1998.

[108] L. Spahr, E. Giostra, J.-L. Frossard, S. Bresson-Hadni, L. Rubbia-Brandt, and A. Hadengue, “Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis,” Journal of Hepatology, vol. 41, no. 2, pp. 229–234, 2004.

[109] P. S. Ribeiro, H. Cortez-Pinto, S. Solá et al., “Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients,” American Journal of Gastroenterology, vol. 99, no. 9, pp. 1708–1717, 2004.

[110] Y. Iimuro, M. Luster, H. Kono, and R. G. Thurman, “Antibodies to tumor necrosis factor α stimulates hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat,” Hepatology, vol. 26, no. 6, pp. 1530–1537, 1997.

[111] N. Enomoto, Y. Takei, M. Hirose et al., “Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production,” Gastroenterology, vol. 123, no. 1, pp. 291–300, 2002.

[112] Z. Song, Z. Zhou, M. Song et al., “Alcohol-induced S-adenosylhomocysteine accumulation in the liver sensitizes to TNF hepatotoxicity: possible involvement of mitochondrial S-adenosylmethionine transport,” Biochemical Pharmacology, vol. 74, no. 3, pp. 521–531, 2007.

[113] Z. Song, Z. Zhou, S. Uriarte et al., “S-adenosylhomocysteine sensitizes to TNF-α hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease,” Hepatology, vol. 40, no. 4, pp. 989–997, 2004.

[114] J. G. Pastorino and J. B. Hock, “Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition,” Hepatology, vol. 31, no. 5, pp. 1141–1152, 2000.

[115] C. García-Ruiz, A. Morales, A. Ballesta, J. Rodés, N. Kaplowitz, and J. C. Fernández-Checa, “Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 193–201, 1994.

[116] A. Cahill, G. J. Stabyle, X. Wang, and J. B. Hock, “Chronic ethanol consumption causes alterations in the structural integrity of mitochondrial DNA in aged rats,” Hepatology, vol. 30, no. 4, pp. 881–888, 1999.

[117] A. Colell, C. Garcia-Ruiz, M. Miranda et al., “Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor,” Gastroenterology, vol. 115, no. 6, pp. 1541–1551, 1998.
S. C. Pappas, “Good science behind hepatitis C virus antiviral drug development: necessary but not sufficient,” *Hepatology*, vol. 46, no. 5, pp. 1317–1319, 2007.

J. G. McHutchison, B. R. Bacon, S. C. Gordon et al., “Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus,” *Hepatology*, vol. 46, no. 5, pp. 1341–1349, 2007.

C. J. McClain, Z. Song, S. S. Barve, D. B. Hill, and I. Deaciuc, “Recent advances in alcoholic liver disease. IV. Dysregulated..."
cytokine metabolism in alcoholic liver disease,” *American Journal of Physiology*, vol. 287, no. 3, pp. G497–G502, 2004.

[148] H. Tilg, R. Jalan, A. Kaser et al., “Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis,” *Journal of Hepatology*, vol. 38, no. 4, pp. 419–425, 2003.

[149] J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent,” *The New England Journal of Medicine*, vol. 345, no. 15, pp. 1098–1104, 2001.

[150] Y. Yamada, I. Kirillova, J. J. Peschon, and N. Fausto, “Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 4, pp. 1441–1446, 1997.

[151] K. V. N. Menon, L. Stadheim, P. S. Kamath et al., “A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis,” *American Journal of Gastroenterology*, vol. 99, no. 2, pp. 255–260, 2004.

[152] N. C. Boetticher, C. J. Peine, P. Kwo et al., “A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis,” *Gastroenterology*, vol. 135, no. 6, pp. 1953–1960, 2008.

[153] V. Purohit and D. Russo, “Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium,” *Alcohol*, vol. 27, no. 1, pp. 3–6, 2002.

[154] P. Greenwel, J.-A. Dominguez-Rosales, G. Mavi, A. Maria Rivas-Estilla, and M. Rojkind, “Hydrogen peroxide: a link between acetaldehyde-elicited a1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells,” *Hepatology*, vol. 31, no. 1, pp. 109–116, 2000.

[155] N. Nieto, S. L. Friedman, and A. I. Cederbaum, “Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells,” *Journal of Biological Chemistry*, vol. 277, no. 12, pp. 9853–9864, 2002.

[156] G. Svegliati-Baroni, Y. Inagaki, A.-R. Rincon-Sanchez et al., “Early response of a2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent,” *Hepatology*, vol. 42, no. 2, pp. 343–352, 2005.

[157] A. Chen, “Acetaldehyde stimulates the activation of latent transforming growth factor-β1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells,” *Biochemical Journal*, vol. 368, no. 3, pp. 683–693, 2002.

[158] A. Canbay, A. E. Feldstein, H. Higuchi et al., “Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression,” *Hepatology*, vol. 38, no. 5, pp. 1188–1198, 2003.

[159] M. Matsuoka and H. Tsukamoto, “Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenetic role in alcoholic liver fibrogenesis,” *Hepatology*, vol. 11, no. 4, pp. 1059–1064, 1990.

[160] W.-I. Jeong and B. Gao, “Innate immunity and alcoholic liver fibrosis,” *Journal of Gastroenterology and Hepatology*, vol. 23, supplement 1, pp. S112–S118, 2008.

[161] F. Marra, S. Aleffi, S. Galastri, and A. Provenzano, “Mononuclear cells in liver fibrosis,” *Seminars in Immunopathology*, vol. 31, no. 3, pp. 345–358, 2009.

[162] Y.-H. Paik, R. F. Schwabe, R. Bataller, M. P. Russo, C. Jobin, and D. A. Brenner, “Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells,” *Hepatology*, vol. 37, no. 5, pp. 1043–1055, 2003.

[163] E. Seki, S. De Minicis, C. H. Österreicher et al., “TLR4 enhances TGF-β signaling and hepatic fibrosis,” *Nature Medicine*, vol. 13, no. 11, pp. 1324–1332, 2007.

[164] T. Luedde and C. Trautwein, “A molecular link between inflammation and fibrogenesis: the bacterial microflora influences hepatic fibrosis via toll-like receptor 4-dependent modification of transforming growth factor-beta signaling in hepatic stellate cells,” *Hepatology*, vol. 47, no. 3, pp. 1089–1091, 2008.

[165] C. A. Casey, A. NANJI, A. I. Cederbaum, M. Adachi, and T. Takahashi, “Alcoholic liver disease and apoptosis,” *Alcoholism: Clinical and Experimental Research*, vol. 25, no. 5, 2001.

[166] M. M. Hassan, L.-Y. Hwang, C. J. Hatten et al., “Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus,” *Hepatology*, vol. 36, no. 5, pp. 1206–1213, 2002.

[167] G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, “Hepatocellular carcinoma in cirrhosis: incidence and risk factors,” *Gastroenterology*, vol. 127, pp. S53–S50, 2004.

[168] I.-M. Yuan, S. Govindarajan, K. Arakawa, and M. C. Yu, “Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S,” *Cancer*, vol. 101, no. 5, pp. 1009–1017, 2004.

[169] K. Moriya, K. Nakagawa, T. Santa et al., “Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis,” *Cancer Research*, vol. 61, no. 11, pp. 4365–4370, 2001.

[170] G. Perlemuter, A. Sabile, P. Letteron et al., “Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis,” *FASEB Journal*, vol. 16, no. 2, pp. 185–194, 2002.

[171] T. Kawaguchi, T. Yoshida, M. Harada et al., “Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3,” *American Journal of Pathology*, vol. 165, no. 5, pp. 1499–1508, 2004.

[172] K. Machida, H. Tsukamoto, H. Mkrtchyan et al., “Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 5, pp. 1548–1553, 2009.

[173] K. Machida, J. Liu, H. Arakawa, and H. Tsukamoto, “TLR4-dependent Nanog+ cancer stem cells exhibit defective TGF-beta signaling,” *Hepatology*, vol. 50, supplement, p. A871, 2009.

[174] K. Koike, T. Tsutsumi, H. Miyoshi et al., “Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis,” *Journal of Gastroenterology and Hepatology*, vol. 23, 1, pp. 587–591, 2008.

[175] S. W. French, J. Oliva, B. A. French, J. Li, and E. Bardag-Gorce, “Alcohol, nutrition and liver cancer: role of toll-like receptor signaling,” *World Journal of Gastroenterology*, vol. 16, no. 11, pp. 1344–1348, 2010.

[176] Y. Tang, K. Kitisin, W. Jogoonoori et al., “Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 7, pp. 2445–2450, 2008.